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Aims: Glucosamine has been safely used to relieve osteoarthritis in humans, but the precise 2 
mechanism underlying its efficacy is still unclear.  In this study, we investigated the direct 3 
effects of glucosamine and related compounds on mast cell mediated inflammation using 4 
cultured mast cells and an animal model. 5 
Main methods: Dinitrophenyl (DNP)-IgE sensitized rat basophilic leukemia RBL-2H3 cells 6 
were treated with glucosamine-HCl (GlcN-HCl), N-acetylglucosamine (GlcNAc), chitin 7 
oligomer or chitosan oligomer.  Cells were stimulated by DNP-BSA to induce degranulation 8 
and released β-hexosaminedase was determined colorimetrically to measure the degree of 9 
degranulation.  Dinitrofluorobenzene (DNFB) sensitized BALB/c mice were administrated 10 
orally with 1 or 0.1 mg GlcN-HCl or GlcNAc for 6 days.  One h after the final administration, 11 
mice was challenged by DNFB to induce ear swelling. 12 
Key findings: GlcN-HCl significantly inhibited the antigen-induced degranulation of RBL-13 
2H3 cells at higher than 0.01 mg/mL for 24 h-treatment while GlcNAc, a chitin oligomer and 14 
a chitosan oligomer had no effect.  GlcN-HCl also suppressed intracellular calcium 15 
mobilization.  GlcN-HCl and GlcNAc significantly suppressed the antigen-induced up-16 
regulation of TNF-α and IL-6 mRNA.  Ear swelling and histamine levels of plasma and ear in 17 
DNFB-treated mice were significantly suppressed by oral administration of GlcN-HCl or 18 
GlcNAc (0.1 and 1 mg) for 6 days. 19 
Significance: Our results strongly suggest that GlcN-HCl and GlcNAc have anti-20 
inflammatory effects in vivo by suppressing the activation of mast cells. 21 




Glucosamine, a naturally occurring amino-monosaccharide, is an essential component 2 
of glycosaminoglycans in almost all human tissues, and glycosaminoglycans are highly 3 
concentrated in connective and cartilage tissues (Laverty et al. 2005).  Glucosamine and 4 
related compounds, which are used as dietary supplements, appear to be safe and are widely 5 
marketed for pain relief of osteoarthritis.  In fact, numerous studies have shown that 6 
glucosamine supplements provide symptomatic relief for osteoarthritis and can normalize 7 
cartilage metabolism (Kim et al. 2005).  However, clinical trials have yielded conflicting 8 
results and the precise mechanism of the effects of glucosamine on arthritis is still obscure.  9 
Recent studies raise questions about the positive effects of glucosamine sulfate on pain and 10 
structural changes associated with osteoarthritis (Felson and Mcalindon 2000; Mcalindon et 11 
al. 2004; Felson 2008).  One speculative mechanism for the efficacy of glucosamine is its 12 
direct effect on inflammatory reactions.  There have been several reports about the potential 13 
immunoregulatory ability of glucosamine (Forchhammer et al. 2003; Meininger et al. 2000).  14 
Glucosamine inhibits IL-1β-induced NF-κB activation and the production of 15 
proinflammatory cytokines in human chondrocytes (Gouze et al. 2002; Shikhman et al. 2001), 16 
and suppresses the release of cytokines from T cells by disturbing the functions of antigen 17 
presenting cells (APCs) and by inhibiting CD3-induced T cell proliferation (Zhang et al. 18 
2005). 19 
Mast cells are commonly found at sites of contact with the outside environment and 20 
they play pivotal roles in inflammation and immediate-type allergic reactions.  Degranulation 21 
of mast cells causes the secretion of biologically active substances including histamine, 22 
eicosanoids, proteolytic enzymes, cytokines and chemokines.  Cytokines released after 23 
degranulation, such as interleukin-6 (IL-6), IL-8 and tumor necrosis factor-alpha (TNF-α), 24 
induce the late-phase allergic reactions and allergic inflammation via the recruitment of 25 
 4 
immune cells to the inflamed site (Feldmann et al. 1996).  It is well known that the 1 
degranulation of mast cells is induced by multivalent antigen-IgE crosslinking and the 2 
aggregation of high affinity IgE receptor I (Kabu et al. 2006).  The aggregation of high 3 
affinity IgE receptor I triggers intracellular signaling pathways, such as the phosphorylation of 4 
protein kinases and the influx of intracellular Ca2+.  Based on this background, the assay for 5 
degranulation of mast cells has been used for screening of anti-inflammatory natural 6 
compounds. 7 
Chitin is a polymer of N-acetylglucosamine found abundantly in the exoskeleton of 8 
crustaceans and insects and in the cell walls of fungi (Shibata et al. 2000; Georgopapadakou 9 
and Tkacz 1995).  Chitosan, a polymer of glucosamine, is obtained by the deacetylation of 10 
chitin under alkaline conditions.  N-acetylglucosamine and glucosamine are industrially 11 
produced by the hydrolysis of chitin and chitosan.  Glucosamine-related products, such as N-12 
acetylglucosamine, glucosamine, chitin and chitosan, have been used extensively to manage 13 
several biological functions.  Especially, chitosan possesses many functional properties such 14 
as biodegradability, immunological and antibacterial activities, and wound-healing (Kuma et 15 
al. 2004) and is used in functional foods and drugs.  However, there has been no report 16 
concerning the effect of glucosamine and related compounds on the degranulation of mast 17 
cells. 18 
The objectives of this study were to investigate the anti-inflammatory activity of 19 
glucosamine and related compounds using cultured mast cells and an animal model, and to 20 
clarify the mechanism underlying its activity.   21 
 22 
Materials and methods 23 
Materials 24 
 5 
Glucosamine-HCl (GlcN-HCl), N-acetylglucosamine (GlcNAc), chitin oligomer (2-1 
7mers of GlucNAc) and chitosan oligomer (less than 10mers of GlcN) were kindly provided 2 
by Nippon Suisan Kaisha, Ltd. (Tokyo, Japan).   3 
 4 
β-Hexosaminidase release assay 5 
Rat basophilic leukemia RBL-2H3 cells (Health Science Resources Bank, Osaka, 6 
Japan) were cultured in RPMI-1640 medium containing 10% FBS and supplemented 7 
antibiotics (100 unit/mL penicillin and 100 μg/mL streptomycin) at 37℃  in humidified 8 
atmosphere in the presence of 5% CO2.  The degree of degranulation of RBL-2H3 cells 9 
stimulated by IgE-antigen was determined by the β-hexosaminidase release assay (Nakano et 10 
al. 2005).  Cells were seeded in 96-well plates (3 × 10
4 
cells/well) with or without 0.45 μg/mL 11 
anti-dinitrophenyl (DNP) IgE (Sigma Chemical Co, St. Louis, MO, USA).  After overnight 12 
incubation, the sensitized or unsensitized cells were washed twice with serum-free RPMI-13 
1640 medium, and then were treated for 4 or 24 h with the indicated concentration of GlcN-14 
HCl, GlcNAc, chitin oligomer or chitosan oligomer dissolved in serum-free RPMI-1640 15 
medium.  After washing twice with Tyrode’s buffer (1.17 mM NaCl, 5.4 mM KCl, 2.0 mM 16 
CaCl2, 1.0 mM MgCl2, 5.6 mM glucose, 25 mM HEPES, 0.1% BSA, pH 7.7), the cells were 17 
incubated with 120 μL/well Tyrode’s buffer containing 1 μg/mL DNP-BSA (Molecular 18 
Probes, Eugene, OR, USA) for 30 min.  The supernatants were collected, and cell lysates 19 
were obtained in Tyrode’s buffer containing 0.1% Triton X-100 (Sigma).  Aliquots (50 µL) of 20 
each supernatant and cell lysate were incubated with 50 µL 5 mM p-nitrophenyl-N-acetyl-β-21 
D-glucosaminide (Sigma) in 0.1 M citrate buffer (pH 4.5) at 37℃ for 1 h.  The reaction was 22 
terminated by the addition of 0.1 M NaHCO3/Na2CO3 (pH 10.0).  p-Nitrophenol, the product 23 
of the reaction, was detected by optical absorbance at 405 nm.  The percentage of β-24 
hexosaminidase released was calculated as follows, 25 
 6 
β-hexosaminidase release (%) = supernatant OD value of the stimulated cells / (the cell 1 
lysate OD value + supernatant OD value of the stimulated cells). 2 
 3 
Measurement of cytosolic Ca2+ concentration 4 
Cytosolic Ca2+ concentrations were measured using of the fluorescent indicator Fluo-5 
4/AM (Dojindo Laboratories, Kumamoto, Japan) (Kempuraj et al. 2005; Takahashi et al. 6 
1999).  RBL-2H3 cells were cultured overnight in 96-well culture plates at 1.5 × 10
4 7 
cells/well with 0.45 μg/mL anti-DNP IgE.  The cells were treated for 4 h with 1 mg/mL of 8 
each glucosamine-related compound in RPMI-1640 medium.  The treated cells were washed 9 
twice and loaded with 4 μM Fluo-4/AM in Tyrode’s buffer at 37°C for 1 h.  After washing 10 
twice with Tyrode’s buffer, the cells were stimulated with 1 μg/mL DNP-BSA for 90 sec.  11 
Intracellular calcium mobilization was detected at 485 nm excitation wavelength and 535 nm 12 
emission wavelength with a Wallac 1420 ARVOSX-FL spectrophotometer (Wallac, Waltham, 13 
MA, USA). 14 
 15 
Western blot analysis 16 
IgE-sensitized cells were treated with 1 mg/mL GlcN-HCl or GlcNAc for 4 h.  The cells 17 
were stimulated by 1µg/mL DNP-BSA for 5 min and then cells were lysed by incubation for 18 
30 min on ice with lysis buffer (25 mM Tris buffered saline, 50 mM sodium fluoride, 1 mM 19 
sodium orthovanadate and protease inhibitor cocktail (Roche, Basel, Switzerland)) containing 20 
1% Triton X-100.  For immunoprecipitation of Lyn, equal amount of protein (200 µg) of cell 21 
lysates were incubated with Lyn specific antibodies (Santa Cruz Biotechnology, Inc, Santa 22 
Cruz, CA) coupled to protein G-sepharose (Sigma Chemical Co, St. Louis, MO) with slow 23 
rotation overnight at 4°C.  Each precipitated protein was separated by SDS-PAGE, and were 24 
then transferred to PVDF membranes (Millipore, Billerica, MA, USA).  The membranes were 25 
 7 
blocked with Blocking One-P (Nacarai Tesque, Inc., Kyoto, Japan).  Lyn and phosphorylated 1 
Lyn were probed with anti-phospho-Lyn antibody (Sigma) and anti-Lyn antibody at 1:1000 2 
dilution for 2 h.  For detecting ERK1/2 and phospho-ERK1/2, equal protein of each cell 3 
lysates (20 µg) was separated by SDS-PAGE and transferred to PVDF membranes.  After 4 
blocking, ERK1/2 and phospho-ERK1/2 were probed with anti-ERK1/2 antibody (Cell 5 
signaling technology, Inc., Danvers, MA) and anti-phospho-ERK1/2 antibody (Cell signaling 6 
technology, Inc) at 1:1000 dilution for 2 h.  HRP-anti-rabbit-antibody (R&D Systems, Inc., 7 
Minneapolis, MN) was used as the secondary antibody at 1:500 dilutions for 1 h.  Detection 8 
was performed using Chemi-Lumi One L (Nacalai) and image-analyzer LAS-3000 9 
(FUJIFILM, Tokyo, Japan). 10 
 11 
Quantification of TNF-α and IL-6 mRNAs by real-time RT-PCR 12 
IgE-sensitized cells were treated with the indicated concentration of each glucosamine-13 
related compound for 4 h as described above.  After washing twice, cells were stimulated 14 
with 1 µg/mL DNP-BSA for 30 min at 37℃.  Cells were washed sufficiently and total RNAs 15 
were extracted using the Sepasol reagent (Nacalai Tesque, Inc. Kyoto, Japan) according to the 16 
manufacturer’s instructions.  RNAs were treated with RNase-free DNase (Invitrogen, 17 
Carlsbad, CA, USA) to remove contaminating genomic DNA.  After inactivating DNase by 18 
heating at 65℃ for 10 min, each RNA was transcribed to cDNA using SuperScript RNaseⅡ 19 
reverse transcriptase (Invitrogen, Carlsbad, CA, USA) with random hexamers at 25℃ for 10 20 
min and then at 42℃ for 50 min.  The reactions were stopped by incubation at 70℃ for 15 21 
min and then 6 µL of each mixture, 10 µL iQ SYBR Green supermix (Bio-Rad Laboratories, 22 
Hercules, CA, USA) and 2 µL TNF-α, IL-6 or GAPDH gene-specific primers (forward and 23 
reverse) were mixed in a final volume of 20 µL. Primers used for the quantification of each 24 
gene are listed in Table 1.  Primer pairs were selected to yield gene-specific single amplicons 25 
 8 
based on the analyses by melting curves and by agarose gel electrophoresis.  Real-time 1 
quantitative PCR was performed using a DNA Engine Opticon system (Bio-Rad 2 
Laboratories).  The thermal cycler parameters were as follows: 3 min at 95℃ for one cycle, 3 
followed by amplification for 40 cycles with melting for 15 seconds at 95℃  and with 4 
annealing and extension for 30 seconds at 60℃.  Values were normalized using GAPDH as 5 
an endogenous internal standard. 6 
 7 
Measurement of DNFB-induced mouse ear swelling 8 
Six-week-old female BALB/c mice were purchased from Japan SLC Inc. (Shizuoka, 9 
Japan).  The animals were housed at 25℃ with a 12-hour light/dark cycle and were allowed 10 
free access to commercial chow (Oriental Yeast Co., LTD., Tokyo, Japan) and tap water.  11 
Animal experiments were performed in accordance with the guidelines of Kyoto University 12 
for the use and care of laboratory animals. 13 
In vivo anti-allergic activity was tested by the dinitrofluorobenzene (DNFB) -induced 14 
contact hypersensitivity reaction (Maeda et al. 2008).  The dorsal skin of each mouse was 15 
shaved and 100 µL 0.5% DNFB in acetone-soybean oil (4:1) was applied to that area to 16 
sensitize the mice.  GlcN-HCl or GlcNAc (0.1 or 1 mg/mouse) was administrated orally once 17 
a day for 6 days.  One h after the final administration, both right and left ears were challenged 18 
with 20 µL 0.5% DNFB in acetone-soybean oil (4:1).  The thickness of the right ear was 19 
measured with a Dial Thickness Gauge (Mitutoyo Co., Kanagawa, Japan) 0, 6 and 24 h after 20 
the DNFB challenge.  The degree of ear swelling was expressed as the percentage of the 21 
thickness of the ear measured before DNFB challenge.  Twenty four hour after DNFB 22 
treatment, blood was collected and mice were sacrificed under anesthesia.  Left ear was fixed 23 
by formalin solution, and each paraffin section was stained by hematoxylin and eosin (HE) to 24 
observe morphological changes.  The amount of TNF-α in the right ear was measured by 25 
 9 
ELISA kit (Thermo Scientific, Yokohama, Japan).  Histamine in the plasma and the right ear 1 
was measured by HPLC with fluorescent detection (Yoshitake et al. 2003).  2 
 3 
Statistical analysis 4 
Data are reported as means ± SD. Statistical analyses were performed by paired-t-test 5 
or one-way analysis of variance (ANOVA) with Dunnett’s test to identify levels of 6 
significance between the groups. 7 
 8 
Results 9 
Effect of glucosamine and related compounds on the antigen-induced degranulation of RBL-10 
2H3 cells 11 
As an indicator of the degranulation of RBL-2H3 cells, the release of β-hexosaminidase 12 
from the cells was measured.  Pre-treatment with 1 mg/mL GlcN-HCl for 4 h significantly 13 
reduced the release of β-hexosaminidase from sensitized RBL-2H3 cells stimulated with 1 14 
µg/mL DNP-BSA for 30 min (Fig. 1A).  The release of β-hexosaminidase from cells treated 15 
with 1 mg/mL GlcN-HCl for 4h was inhibited by approximately 50% compared to cells 16 
treated with antigen alone.  Treatment with GlcN-HCl for 24h significantly inhibited the 17 
release of β-hexosaminidase at more than 0.01 mg/mL (Fig.1B).  In contrast, GlcNAc, a 18 
chitin oligomer or a chitosan oligomer had no effect on the antigen-induced degranulation of 19 
mast cells (Fig. 1A and B).  GlcN-HCl, GlcNAc, chitin oligomer and chitosan oligomer had 20 
no direct effect on the enzyme activity of β-hexosaminidase (data not shown). 21 
 22 
Effect of glucosamine and related compounds on the expression of proinflammatory cytokines 23 
We examined whether glucosamine and related compounds could modulate the 24 
expression of proinflammatory cytokines (TNF-α and IL-6) induced by antigen in RBL-2H3 25 
 10 
cells because those cytokines from mast cells are involved in late-phase allergy.  Both GlcN-1 
HCl and GlcNAc significantly suppressed the antigen-induced expression of TNF-α and IL-6 2 
mRNAs more than 60% compared with the control treated with antigen alone, while the 3 
chitin oligomer and the chitosan oligomer had no significant effect (Fig. 2A and B). 4 
 5 
Effect of glucosamine-HCl and N-acetylglucosamine on intracellular Ca2+ mobilization and 6 
the activation of intracellular signaling molecules 7 
It is well known that elevation of the intracellular Ca2+ concentration triggers the 8 
degranulation of mast cells.  We evaluated the effects of GlcN-HCl, GlcNAc, chitin oligomer 9 
and chitosan oligomer on intracellular Ca2+ mobilization in RBL-2H3 cells.  The results were 10 
similar to the effects on degranulation as described above.  RBL-2H3 cells stimulated with 1 11 
µg/mL DNP-BSA had increased intracellular Ca2+ levels at 90 sec.  Pre-treatment with 1 12 
mg/mL GlcN-HCl for 4 h significantly suppressed the antigen-induced elevation of 13 
intracellular Ca2+ compared to cells treated with antigen alone (Fig. 3A).  GlcNAc, chitin 14 
oligomer and chitosan oligomer had no effect on the intracellular calcium mobilization.  We 15 
examined the effect of GlcN-HCl and GlcNAc on the tyrosine phosphorylation of Lyn which 16 
is critical for degranulation.  The level of phosphorylated Lyn was increased 2-fold by 17 
stimulation with DNP-BSA for 5 min.  In GlcN-HCl-treated cells, the DNP-BSA-induced 18 
tyrosine phosphorylation of Lyn was significantly lower than in control cells (Fig. 3B).  On 19 
the other hand, the activation of ERK1/2, which leads to the up-regulation of cytokines gene 20 
expression, in both GlcN-HCl and GlcNAc treated cells was significantly reduced as 21 
compared with that of the control cells (Fig.3C). 22 
 23 
Effect of glucosamine-HCl and N-acetylglucosamine on DNFB-induced ear swelling in 24 
BALB/c mice 25 
 11 
To investigate anti-inflammatory activity in vivo, the effect of oral administration of 1 
GlcN-HCl or GlcNAc on DNFB-induced mouse ear swelling was evaluated.  DNFB-induced 2 
ear swelling is a model for contact hypersensitivity and is caused by cytokines and infiltrating 3 
neutrophils.  We examined the effects of dietary GlcN-HCl and GlcNAc on DNFB-induced 4 
immediate (6 h) and delayed (24 h) hypersensitivity.  Oral administration of GlcN-HCl or 5 
GlcNAc for 6 days (0.1 and 1 mg/mouse/day) significantly inhibited DNFB-induced ear 6 
swelling in mice at both 6 h and 24 h after the DNFB challenge (Fig. 4A and B). 7 
Swelling of hypodermal tissue and the infiltration of inflammatory cell were observed 8 
in the ear section by histochemical analysis of hematoxylin-eosin staining.  In the ear of the 9 
mice administrated GlcN-HCl or GlcNAc, the pathological changes induced by DNFB 10 
treatment were mitigated (Fig.5A).  The content of TNF-α in the ear of the mice 11 
administrated of GlcN-HCl and GlcNAc tended to be reduced as compared with control mice.  12 
Oral administration of GlcN-HCl and GlcNAc significantly reduced the concentration of 13 
histamine in both ear and plasma of DNFB-treated mice (Fig.5C and D).   14 
 15 
Discussion 16 
In the present study, we demonstrated that GlcN-HCl and GlcNAc have different 17 
effects on mast cell activation.  GlcN-HCl suppresses the degranulation and up-regulation of 18 
inflammatory cytokine gene expression in mast cells while GlcNAc inhibits only the cytokine 19 
gene expression.  Chitin and chitosan, which are oligomers of GlcNAc and GlcN, respectively, 20 
did not affect the antigen-induced reaction of mast cells.  Oral administration of GlcN-HCl or 21 
GlcNAc (0.1 or 1 mg/day) for 6 days suppressed the ear swelling and histamine levels of 22 
plasma and ear in DNFB-treated mice.  These results strongly suggested that the anti-23 
inflammatory effects of dietary GlcN-HCl or GlcNAc in vivo are caused by the inhibition of 24 
antigen-induced release of chemical mediators and cytokines from mast cells.   25 
 12 
Mast cells are mainly involved in the inflammation of type I allergy due to the secretion 1 
of chemical mediators such as histamine, leukotriene and inflammatory cytokines (Kabu et al. 2 
2006).  It is well understood that antigen-IgE binding initiates intracellular signaling cascades 3 
such as the phosphorylation of Lyn kinase which leads to the phosphorylation of mitogen-4 
activated protein kinase (MAPK), the mobilization of intracellular Ca2+ and degranulation 5 
(Kabu et al. 2006; Gilfilan and Tkaczyk. 2006).  In the present study, we focused on the 6 
effects of glucosamine and related compounds on the degranulation of mast cells.  GlcN-HCl, 7 
but not GlcNAc, significantly inhibited the antigen-induced degranulation, intracellular Ca2+ 8 
influx, and the phosphorylation of Lyn in mast cells.  The antigen-induced intracellular 9 
signaling in mast cells involves the phosphorylation of mitogen-activated protein kinase 10 
(MAPK) followed by the activation of nuclear factor-kappa B (NF-κB).  Activated NF-kB up-11 
regulates TNF-α and IL-6 expression.  Proinflammatory cytokines are secreted from 12 
degranulated mast cells and induce the infiltration of leukocytes and macrophages to inflamed 13 
sites.  Activated leukocytes and macrophages release inflammatory cytokines and induce 14 
cellular dysfunction (Feldmann et al 1996).  It has been shown that GlcN and GlcNAc have 15 
inhibitory effects on the IL-1-mediated intracellular signaling cascade by reducing the 16 
activation of NF-κB in chondrocytes (Gouze et al. 2002; Largo et al. 2003).  GlcN suppresses 17 
the inflammation induced by the activation of neutrophils and synoviocytes but GlcNAc has 18 
no effect (Hua et al. 2002, Hua et al 2007).  In the present study, we show that GlcN-HCl 19 
inhibits both degranulation and cytokine expression while GlcNAc only suppresses cytokine 20 
expression.  Our data support that GlcN-HCl inhibits both degranulation and the up-21 
regulation of cytokine genes by suppressing the phosphorylation of Lyn and ERK1/2, and that 22 
GlcNAc only affects ERK1/2 phosphorylation, a regulator of cytokine genes. 23 
Oral administration of GlcN-HCl or GlcNAc suppresses immediate (6 h) and delayed 24 
(24 h) reactions in DNFB-induced contact allergy model mice.  DNFB is used as a contact 25 
 13 
allergen to induce ear inflammatory reactions including the degranulation of mast cells (Kabu 1 
et al. 2006).  It has been reported that GlcN is rapidly absorbed after oral administration 2 
(Persiani et al. 2005; Pashkova et al. 2009).  The absorption rate of the intact form of GlcNAc 3 
is lower than GlcN and appreciable amounts of GlcNAc would be deacetylated during the 4 
intestinal absorption (Liu et al. 2008; Capps et al. 1966; Robinson 1968).  In the present study, 5 
oral administration of GlcN-HCl or GlcNAc significantly reduced the levels of histamine in 6 
plasma and ear in DNFB-treated mice.  Histamine is released from activated mast cells in 7 
mucosal tissue and connective tissue.  Our data strongly suggest that GlcN hydrolysed from 8 
GlcNAc after oral administration inhibits DNFB-induced degranulation of mast cells in mice. 9 
Mast cells provide a critical cellular link between soluble factors and synovial eruptions 10 
and can contribute to the pathogenic mechanisms in the synovium that result in arthritis (Lee 11 
et al. 2002; Nigrovic and Lee 2007; Eklund 2007).  Thus, mast cells play a very important 12 
role in the inflammation of arthritis.  A recent study revealed that mast cells are involved in 13 
cellular dysfunction via activation induced by immunocomplexes (Complement 3a, 14 
Complement 5a receptor and low affinity IgG receptor Ⅲ) (Baumann et al. 2001).  This 15 
suggests that the immunocomplexes induce the degranulation of mast cells and the migration 16 
of neutrophilis by cytokines released from mast cells and finally evoke inflammation in the 17 
joint (Lee et al. 2002).  GlcN-HCl and GlcNAc would be the potential effective compounds to 18 
relieve inflammation caused by the activation of mast cells.  On the other hand, there are 19 
some reports that suggest glucosamine has no effect for osteoarthritis (MacAlindon et al. 20 
2004; Felson 2008).  The conflicts in clinical trials of glucosamine supplements for 21 
osteoarthritis might be due to inter-patient variation in the pathogenic mechanism and the 22 
pathological process. 23 
24 
 14 
Figure legends 1 
Fig. 1.  Effect of glucosamine and related compounds on antigen-induced degranulation of 2 
RBL-2H3 cells. 3 
DNP-IgE sensitized cells were incubated with the indicated concentrations of GlcN-4 
HCl, GlcNAc, chitin oligomer or chitosan oligomer for 4 h (A) or 24 h (B) and were then 5 
stimulated with 1 µg/mL DNP-BSA for 30 min.  Released β-hexosaminidase was measured.  6 
Values are means ± SD, n = 4.  * Significantly different from control, P < 0.05.  Non, non 7 
stimulation; Con, stimulation; GlcN, glucosamine-HCl; GlcNAc, N-acetylglucosamine; 8 
Chitin, chitin oligomer; Chitosan, chitosan oligomer. 9 
 10 
Fig. 2.  Effect of glucosamine and related compounds on the mRNA expression of 11 
proinflammatory cytokines in RBL-2H3 cells. 12 
Sensitized cells were incubated with 1 mg/mL GlcN-HCl, GlcNAc, chitin oligomer or 13 
chitosan oligomer for 4 h and then cells were stimulated with 1 µg/mL DNP-BSA for 30 min.  14 
The mRNA expression levels of TNF-α (A) and IL-6 (B) were quantified by real-time RT-15 
PCR.  Data are presented as fold induction relative to the unstimulated cells.  Values are 16 
means ± SD, n = 4.  * Significantly different from control, P < 0.05.  Abbrevations are the 17 
same as those given for Fig. 1. 18 
 19 
Fig. 3  Effect of glucosamine-HCl and N-acetylglucosamine on DNP-BSA induced 20 
intracellular Ca2+ mobilization and activation of intracellular molecules. 21 
(A) Sensitized cells were loaded with 4 µM Ca2+ indicator Fluo-4/AM for 1 h after 22 
treatment with 1 mg/mL glucosamine or related compounds and were stimulated by 10 23 
mg/mL DNP-BSA for 90 sec.  The fluorescence of Fluo-4 was then measured.  Values are 24 
means ± SD, n = 6.  * Significantly different from control, P < 0.05.  (B, C) Sensitized cells 25 
 15 
were incubated with GlcN-HCl or GlcNAc for 4 h and stimulated with DNP-BSA for 5 min.  1 
Cell lysate was immunoprecipitated with Lyn specific antibody, and then phosphorylation of 2 
Lyn was detected by western blot analysis using anti-phospho-Lyn antibody (B).  3 
Phosphorylation of ERK1/2 in the cell lysate was detected using anti-phospho-ERK1/2 4 
antibody (C).  Western blotting was performed independent three experiments.  Data were 5 
analyzed by the density of bands and represented the intensity of the bands of phosphorylated 6 
Lyn/normal Lyn (B) and phosphorylated ERK/normal ERK (C), as a relative value for that of 7 
the non-stimulated cells.  Values were means±SD, n=3.  * Significantly different from control, 8 
P < 0.05.  Statistical analyses were performed by paired-t-test.  Abbrevations are the same as 9 
those given for Fig. 1. 10 
 11 
Fig. 4  Effect of glucosamine-HCl and N-acetylglucosamine on DNFB-induced ear swelling 12 
in BALB/c mice. 13 
DNFB-sensitized mice were administrated orally with GlcN-HCl or GlcNAc (0.1 or 1 14 
mg) once a day for 6 days.  One hour after the final administration, the mice were challenged 15 
on the ears with 20 µL 0.5% DNFB in acetone-soybean oil (4:1).  Thickness of the ear was 16 
measured at 6 h (A) and at 24 h (B) after treatment with DNFB and values are presented as a 17 
percentage of the thickness of the ear measured before DNFB challenge.  Values are means ± 18 
SD, n=3.  *Significantly different from control, P < 0.05.  Abbrevations are the same as those 19 
given for Fig. 1.  20 
 21 
Fig. 5  Effect of glucosamine-HCl and N-acetylglucosamine on DNFB-induced inflammation. 22 
(A) Twenty-four hours after DNFB-challenge, the ear was fixed by formalin solution 23 
and its paraffin section was stained by hematoxylin and eosin (HE).  Bars indicate 100 µm.  24 
(B)  The contents of TNF-α in the ear were measured by ELISA kit.  Values are means ± SD, 25 
 16 
n=3.  (C, D) Histamine in ear (C) and plasma (D) was determined by HPLC with 1 
spectrofluorometer.  Values are means ± SD, n=3. *Significantly different from control, P < 2 
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